Carterra
High-throughput antibody screening for drug discovery
Aug
2007
Frazier Event
Series A primary investment
Jan
2012
Frazier Event
Series B primary investment
Jan
2012
Frazier Event
Series B primary investment
Jan
2018
Company Event
$10M funding round led by Telegraph Hill Partners
Jan
2020
Company Event
$6M funding round led by Ballast Point Ventures
Dec
2020
Company Event
Equity financing led by PerkinElmer
Dec
2020
Frazier Event
Frazier VC Fund III Series G primary investment
Capital Events Timeline
Company Overview
Carterra develops high-throughput, label-free biomolecular interaction analysis platforms used in therapeutic discovery, with a focus on antibody characterization workflows.
Why We Invested
Carterra's patented microfluidic flow-printing approach is purpose-built for antibody discovery workflows where speed, data depth, and reproducibility matter.
Investment Vehicle
Frazier VC Fund III
Investor
Frazier VC
Founded
2005
Sector
Healthcare & Life Sciences
Legal Name
Carterra, Inc. (formerly Wasatch Microfluidics)
Status
Active
Other Investors
PerkinElmer, Telegraph Hill Partners, Ballast Point Ventures, Revvity, Shepherd Growth Partners, Park City Angels